Regeneron Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1988-01-01
- Employees
- 13.4K
- Market Cap
- $132.4B
- Website
- http://www.regeneron.com
- Introduction
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSu...
A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2023-10-24
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 733
- Registration Number
- NCT06097364
- Locations
- 🇨🇱
Hospital Clinico Universidad de Los Andes, Santiago, Las Condes, Chile
🇮🇱Hadassah Medical Center, Jerusalem, Israel
🇮🇱Rabin Medical Center, Petah Tikva, Israel
A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Patients With Previously Untreated Diffuse Large B-cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2023-10-19
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 904
- Registration Number
- NCT06091865
- Locations
- 🇫🇷
Hopital Saint Vincent-de-Paul, Lille, Nord, France
🇰🇷St. Vincent Hospital - The Catholic University of Korea, Suwon-si, Gyeonggi-do, Korea, Republic of
🇰🇷Yeouido St. Marys Hospital, Seoul, Korea, Republic of
A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Participants With Follicular Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2023-10-19
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 478
- Registration Number
- NCT06091254
- Locations
- 🇪🇸
Hospital Clinico Universitario Valencia, Valencia, Spain
🇪🇸Hospital Universitary and Politecnic La Fe, Valencia, Spain
🇨🇭Kantonsspital Baden, Baden, Aargau, Switzerland
A Non-Interventional Study of Clinical Characteristics and Mortality of US Patients With Fibrodysplasia Ossificans Progressiva (FOP)
- Conditions
- Interventions
- First Posted Date
- 2023-10-03
- Last Posted Date
- 2023-10-25
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 131
- Registration Number
- NCT06064656
- Locations
- 🇺🇸
Regeneron, Tarrytown, New York, United States
Compassionate Use of Vidutolimod
- First Posted Date
- 2023-10-03
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Regeneron Pharmaceuticals
- Registration Number
- NCT06063746
Compassionate Use of Pozelimab and Cemdisiran Combination Therapy in Patients With Paroxysmal Nocturnal Hemoglobinuria
- Conditions
- First Posted Date
- 2023-09-08
- Last Posted Date
- 2023-09-08
- Lead Sponsor
- Regeneron Pharmaceuticals
- Registration Number
- NCT06028594
A Trial to Learn if Receiving ALN-PNP siRNA is Safe and Well Tolerated, and How it Works in Adult Participants With Nonalcoholic Fatty Liver Disease (NAFLD) and a Genetic Risk Factor
- Conditions
- Interventions
- First Posted Date
- 2023-09-06
- Last Posted Date
- 2024-06-20
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 104
- Registration Number
- NCT06024408
- Locations
- 🇰🇷
Severance Hospital, Seoul, Korea, Republic of
🇰🇷Chungbuk National University Hospital, Cheongju-si, Chungcheong Buk-do, Korea, Republic of
🇰🇷CHA Bundang Medical Center, Seongnam-si, Gyeonggi-do, Korea, Republic of
A Natural History Study in Pediatric Participants With Hearing Loss Due to OTOF, GJB2, or GJB2/GJB6 Mutations
- First Posted Date
- 2023-08-31
- Last Posted Date
- 2024-03-06
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 20
- Registration Number
- NCT06019481
- Locations
- 🇺🇸
Nationwide Children's Hospital, Columbus, Ohio, United States
🇺🇸Phoenix Children's Hospital, Phoenix, Arizona, United States
Compassionate Use of Pozelimab in Patients With CD55-Deficient Protein-Losing Enteropathy
- First Posted Date
- 2023-08-22
- Last Posted Date
- 2023-08-22
- Lead Sponsor
- Regeneron Pharmaceuticals
- Registration Number
- NCT06003881
Study to Evaluate an 8 mg Aflibercept (EYLEA®) Prefilled Syringe (PFS)
- Conditions
- Interventions
- First Posted Date
- 2023-08-14
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 35
- Registration Number
- NCT05989126
- Locations
- 🇺🇸
Retina Consultants of Texas, The Woodlands, Texas, United States